Johnson & Johnson (NYSE:JNJ) Posts Earnings Results, Beats Estimates By $0.11 EPS

Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings data on Wednesday. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11, RTT News reports. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.79% and a net margin of 46.34%. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.80 earnings per share. Johnson & Johnson updated its FY24 guidance to $9.97-10.07 EPS and its FY 2024 guidance to 9.970-10.070 EPS.

Johnson & Johnson Stock Down 0.8 %

Johnson & Johnson stock traded down $1.19 during trading on Friday, hitting $154.23. 2,638,000 shares of the company were exchanged, compared to its average volume of 7,301,116. The business’s 50 day moving average is $148.26 and its 200 day moving average is $153.40. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The company has a market capitalization of $371.18 billion, a P/E ratio of 9.68, a PEG ratio of 2.76 and a beta of 0.52. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.22%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Analyst Ratings Changes

A number of equities analysts recently commented on JNJ shares. The Goldman Sachs Group started coverage on Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective on the stock. TD Securities cut their price objective on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday. Bank of America dropped their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. Finally, Sanford C. Bernstein boosted their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $175.29.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.